Ofranergene obadenovec

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, EU4, DNA, Bevacizumab, Malignancy, Radiation, Temozolomide, GBM, Survivin, Neoplasm, Epidemiology, Survival, Forest Law Enforcement and Governance Program, Cancer, Genentech, Immunotherapy, USD, Incidence, VEGF, Health insurance coverage in the United States, Congress of Neurological Surgeons, VBL, AANS, American Association of Neurological Surgeons, Patient, Patent, Ofranergene obadenovec, IDH1, Growth, Merck, FDA, Therapy, Disease, Mobile phone, Health care, Pharmaceutical industry, Glioma

The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.

Key Points: 
  • The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.
  • Epidemiology: Glioma's epidemiology is discussed for the 7MM (United States, EU4 countries, UK, and Japan) from 2019 to 2032.
  • The United States contributed the highest incident cases, with Grade IV glioma being the most prevalent.
  • Market Access and Reimbursement: Reimbursement for rare disease therapies faces challenges due to high costs and lack of policies.

VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

Retrieved on: 
Tuesday, July 19, 2022
Multiple sclerosis, GLOBE, Glioblastoma, U.S. Securities and Exchange Commission, Twitter, Rheumatoid arthritis, OVAL, SEC, Research, Inflammatory bowel disease, Neoplasm, Hand, Risk, PFS, Therapy, Adult, Cancer, Progression-free survival, TEL, OS, Biotechnology, Clinical trial, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Review, YouTube, Company, Patient, LinkedIn, Nasdaq, VBL, Annual report, Form 20-F, NEW, Survival, Ofranergene obadenovec, Paclitaxel, Pharmaceutical industry, Facebook

The trial did not meet the primary endpoints of achieving a statistically significant improvement in progression-free survival (PFS) or overall survival (OS).

Key Points: 
  • The trial did not meet the primary endpoints of achieving a statistically significant improvement in progression-free survival (PFS) or overall survival (OS).
  • Based on this outcome, we plan to discontinue the OVAL trial and will review the data from our ongoing Phase 2 trials in metastatic colorectal cancer and recurrent glioblastoma multiforme to determine next steps with the ofra-vec program.
  • We extend our deepest gratitude to all the patients, families and healthcare professionals who participated in this trial.
  • OVAL (VB-111-701/GOG-3018) was an international, Phase 3, randomized, double-blind, placebo-controlled, clinical trial comparing a combination of ofra-vec (ofranergene obadenovec; VB-111) plus paclitaxel to placebo plus paclitaxel in 409 adult patients with recurrent platinum-resistant ovarian cancer.

VBL Therapeutics to Participate in the Jefferies Healthcare Conference

Retrieved on: 
Tuesday, May 31, 2022
LinkedIn, Therapy, Twitter, VBL, MTT, Blood, Ofranergene obadenovec, Cancer, YouTube, Biogen, Vaccine, Medical imaging, Facebook

Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions.

Key Points: 
  • Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions.
  • Using our novel platform technologies, we have created a pipeline of therapeutics to uniquely address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of currently approved treatments.
  • Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer.
  • To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

Retrieved on: 
Tuesday, May 10, 2022
YouTube, Ofranergene obadenovec, Twitter, Nasdaq, VBL, GLOBE, NEW, TEL, Therapy, M.D, LinkedIn, Solution, Technology, Pharmaceutical industry, Vaccine, Facebook

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications,today announced that it will release first quarter financial results for the period endedMarch 31, 2022onTuesday, May 17before market open.

Key Points: 
  • TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications,today announced that it will release first quarter financial results for the period endedMarch 31, 2022onTuesday, May 17before market open.
  • Professor Dror Harats, M.D, Chief Executive Officer, andSam Backenroth, Chief Financial Officer, will host a conference call at8:30am ETto discuss the results and provide a corporate update.
  • Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications.
  • To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May

Retrieved on: 
Tuesday, May 3, 2022
Monocyte, YouTube, Ofranergene obadenovec, Twitter, Nasdaq, VBL, GLOBE, NEW, TEL, Therapy, LinkedIn, Psych 2: Lassie Come Home, Conference, Inflammation, Technology, Solution, Pharmaceutical industry, Facebook

In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022.

Key Points: 
  • In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022.
  • VBLs lead oncology product candidate, ofra-vec (ofranergene obadenovec; `VB-111`), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors.
  • Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer.
  • To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 28, 2022
Solution, Employment, LinkedIn, TEL, YouTube, Twitter, Nasdaq, GLOBE, Therapy, Technology, NEW, VBL, Ofranergene obadenovec, Financial compensation, Professional Football Compensation Committee, Pharmaceutical industry, Facebook

The option grant has an exercise price of $1.57 per share, the fair market value on the grant date, and will vest and become exercisable beginning one year following the grant, when 33% will vest, with the remainder vesting quarterly over two years subject to the employees continued employment with VBL on such vesting dates.

Key Points: 
  • The option grant has an exercise price of $1.57 per share, the fair market value on the grant date, and will vest and become exercisable beginning one year following the grant, when 33% will vest, with the remainder vesting quarterly over two years subject to the employees continued employment with VBL on such vesting dates.
  • The option has a ten-year term and is subject to the terms and conditions of VBLs Inducement Plan (2022) and the award agreement covering such grant.
  • Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer.
  • To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

Retrieved on: 
Tuesday, April 26, 2022
Annual report, Glioma, DSMC, Fast track (FDA), U.S. Securities and Exchange Commission, PFS, COVID-19, Paclitaxel, Twitter, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Commission, Research, Biologics license application, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Food, YouTube, GLOBE, OS, Patient, LinkedIn, TEL, OVAL, Royal commission, Review, Technology, Nasdaq, Therapy, Solution, SEC, Ofranergene obadenovec, NEW, Fast Track, FDA, BLA, Ovarian cancer, Risk, Mass flow (life sciences), VBL, Form 20-F, Cancer, Survival, Pharmaceutical industry, Facebook

We are pleased to receive FDA Fast Track designation for ofra-vec in platinum-resistant ovarian cancer.

Key Points: 
  • We are pleased to receive FDA Fast Track designation for ofra-vec in platinum-resistant ovarian cancer.
  • The lead clinical program for ofra-vec is the OVAL Phase 3 registration-enabling trial in recurrent platinum-resistant ovarian cancer patients.
  • Ofra-vec has received orphan designations for the treatment of ovarian cancer and for the treatment of glioma by the European Commission.
  • The FDA granted ofra-vec orphan designation for the treatment of malignant glioma and fast track designation for the treatment of rGBM and the treatment of platinum-resistant ovarian cancer.

VLB Therapeutics to Report Year-End 2021 Financial Results on March 23

Retrieved on: 
Monday, March 14, 2022
Ofranergene obadenovec, Solution, Twitter, Therapy, YouTube, Biogen, VBL, LinkedIn, Technology, Vaccine, Medical imaging, Facebook

Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications.

Key Points: 
  • Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications.
  • VBLs lead oncology product candidate, ofranergene obadenovec (`ofra-vec`, or VB-111), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors.
  • Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer.
  • To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

VBL Therapeutics to Participate at March Investor Conferences

Retrieved on: 
Thursday, March 3, 2022
Twitter, YouTube, Technology, LinkedIn, Ofranergene obadenovec, Solution, Therapy, VBL, Biogen, Pharmaceutical industry, Vaccine, Facebook

Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications.

Key Points: 
  • Vascular Biogenics Ltd., operating asVBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications.
  • VBLs lead oncology product candidate, ofranergene obadenovec (`ofra-vec`, or VB-111), is an investigational, first-in-class, targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors.
  • Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer.
  • To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 15, 2022
NEW, YouTube, Solution, TEL, VBL, Ofranergene obadenovec, Nasdaq, Professional Football Compensation Committee, Therapy, Technology, LinkedIn, Twitter, Financial compensation, Employment, GLOBE, Pharmaceutical industry, Facebook

The option grant has an exercise price of $1.51 per share, the fair market value on the grant date, and will vest and become exercisable beginning one year following the grant, when 33% will vest, with the remainder vesting quarterly over two years subject to Mr. Trudeaus continued employment with VBL on such vesting dates.

Key Points: 
  • The option grant has an exercise price of $1.51 per share, the fair market value on the grant date, and will vest and become exercisable beginning one year following the grant, when 33% will vest, with the remainder vesting quarterly over two years subject to Mr. Trudeaus continued employment with VBL on such vesting dates.
  • The option has a ten-year term and is subject to the terms and conditions of VBLs Inducement Plan (2022) and the award agreement covering such grant.
  • Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer.
  • To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.